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Abstract: Immediate-release (IR) pramipexole is indicated for the symptomatic treatment 
of idiopathic Parkinson’s disease (PD), either alone (without levodopa) or in combination 
with levodopa, that is, during the entire progress of disease up to the advanced stage. It is also 
  currently indicated for the treatment of moderate-to-severe primary restless legs syndrome (RLS). 
An extended-release (ER) formulation of pramipexole has been developed to allow a once-daily 
formulation and to provide more stable dopaminergic stimulation. This review summarized the 
pharmacokinetic profile of pramipexole for both the IR and ER formulations, and discussed 
the role of pramipexole in the management of early and advanced PD. The introduction of a 
once-daily formulation of pramipexole poses significant potential advantages for patients and 
this is reflected by relatively stable plasma levels. The most obvious benefit is convenience of 
use and better adherence to treatment schedule. Additional advantages may be represented by 
the opportunity to provide continuous drug delivery in a fashion that could potentially help 
minimize dyskinesia risk if the drug is used early in the disease course.
Keywords: advanced Parkinson’s disease, continuous drug delivery, early Parkinson’s disease, 
extended release, immediate release, pramipexole
Introduction
Pramipexole is a selective dopamine D2 receptor agonist, approved since 1998 in most 
European countries and in 1997 in the US. Pramipexole is indicated for the symptomatic 
treatment of idiopathic Parkinson’s disease (PD), either alone (without levodopa) or 
in combination with levodopa, that is, during the entire progress of disease up to the 
advanced stage. It is also currently indicated for the treatment of moderate-to-severe 
primary restless legs syndrome (RLS).
Since their introduction, dopamine agonists have become a common first-line 
treatment for PD and some patients remain on a dopamine agonist through the entire 
course of their disease. Dopamine agonists are advantageous in several aspects. 
They do not require carrier-mediated transport in the gut or brain. They act directly 
on the dopamine receptors without the need for metabolic modification, release, or 
storage. They also have longer half-lives than levodopa and therefore they produce 
more persistent dopamine receptor stimulation than levodopa. Their metabolism does 
not generate free radicals which are considered one of the most important hazards in 
levodopa treatment, particularly on dopaminergic neurons.1,2 This means there is now 
considerable experience in trials and in clinical practice with dopamine agonists such 
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This review summarizes the pharmacokinetic profile 
of pramipexole for both the immediate release (IR) and 
extended release (ER) formulations, and discusses the role of 
pramipexole in the management of early and advanced PD.
Our review of the literature involved performing searches 
in Medline (1966–February 2011) and the central database in 
the Cochrane Library (1948–2011) with the specific search 
terms: ‘pramipexole’, ‘pramipexole extended release’, 
‘mirapexin’, ‘mirapex’, and ‘dopamine agonist’. Papers 
were considered if they were published in the English peer-
reviewed literature. In addition, reference lists published 
in review papers were systematically checked for relevant 
references, regulatory publications issued by the European 
Committee of Proprietary Medicinal Products and the US 
Food and Drug Administration were reviewed, and recent 
releases of information (congress abstracts and press releases) 
from major PD clinical trials were considered.
Pharmacology
Pramipexole is a synthetic, nonergot, aminothiazole dop-
amine agonist with high relative in vitro specificity and full 
intrinsic activity at the D2 subfamily of dopamine receptors, 
binding with higher affinity to D3 than to D2 or D4 receptor 
subtypes.3 The relevance of D3 receptor binding in PD is 
unknown but it is suggested that the preferential affinity of 
pramipexole for the D3 receptor subtype could contribute 
to efficacy in the treatment of psychiatric symptoms of 
PD-like depression.4 Unlike the ergot dopamine agonists, 
pramipexole has little or no interaction with adrenergic or 
serotonergic receptors,3 which means that pramipexole does 
not appear to exert any fibrotic effects.5
Biochemical and electrophysiological aspects of dopamin-
ergic autoreceptor desensitization have also been described 
previously. It was observed that sustained pramipexole 
administration produced desensitization of D2/D3 and 
5-HT1A cell body autoreceptors, as well as a decrease in 
sensitivity of α2-adrenergic cell body autoreceptors.6
Pharmacokinetic profile
Pramipexole has linear pharmacokinetics over its entire 
therapeutic range. It is rapidly and completely absorbed 
with peak levels appearing in the bloodstream within 
2 hours of oral dosing. It has a high absolute bioavailability 
of .90% and can be administered without regard to meals 
(time to peak concentration is 3–4 hours with food although 
the extent of absorption remains unaffected). Pramipexole 
excretion is primarily renal (90% excreted unchanged in the 
urine) and there is negligible metabolism of pramipexole.7 
The   pharmacokinetic properties of pramipexole at steady-
state concentrations were studied in 16 healthy men 
and women at four dose levels throughout the range 
recommended for Parkinson’s patients. Concentrations of 
pramipexole were proportional to dose, although the drug’s 
pharmacokinetic properties differed between men and 
women. The area under the concentration-time curve for 
each dose level was 35% to 43% greater in women, mainly 
because of a 24% to 27% lower oral clearance. The renal 
clearance of pramipexole accounts for approximately 80% of 
oral clearance, and there was a significant correlation between 
renal and creatinine clearances. The influence of gender 
could not be distinguished from the influence of age and the 
resulting reduced creatinine clearance, but the measurement 
of pharmacokinetic properties produced linear results in 
both men and women.8 Of particular note is the fact that 
pramipexole undergoes almost no hepatic biotransformation 
and was found to exert no potent cytochrome P450 (CYP) 
system inhibition in vitro.9
This lack of hepatic metabolism has been suggested to 
minimize drug–drug interactions, which may be clinically 
relevant as PD predominantly affects the older generation 
who are often prescribed multiple medications.10
Coadministration of other drugs renally secreted by 
the cationic transporter system decreased the pramipexole 
clearance by 9.0% to 17.7%.7 A pharmacokinetic analysis 
in Japanese patients demonstrated that coadministration of 
amantadine decreased the total clearance of pramipexole 
by 25%.11 Organic cation transporters (OCTs), a family 
of polyspecific organic cation transporters responsible for 
the transport of organic cations, including amantadine, 
are involved in the renal uptake of pramipexole across the 
basolateral membrane of the proximal tubular epithelial cells 
in rat.12 Amantadine inhibited the uptake of pramipexole by 
rat OCT1- and rat OCT2-expressing oocytes and rat kidney 
slices in a concentration-dependent manner, suggesting 
that an organic cation-specific mechanism is at least partly 
involved in this drug interaction.12
Pramipexole ER is a nonergolinic dopamine receptor ago-
nist available for use as a once-daily oral treatment for the signs 
and symptoms of early and advanced PD. Continuous dopamin-
ergic stimulation is a therapeutic concept for the development 
of dopamine agonists with continuous, as opposed to discon-
tinuous or pulsatile, stimulation of striatal dopamine receptors. 
This concept derived from studies of the normal basal ganglia 
demonstrating that nigral dopaminergic neurons normally 
fire continuously and striatal dopamine levels are relatively 
constant. Once-daily pramipexole ER and three times daily Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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pramipexole IR have similar exposure over 24 hours. In a Phase 
I trial, where pramipexole IR and ER tablets were assessed in 
fasted state, the minimum and maximum plasma concentration 
(Cmin, Cmax) and exposure (AUC) of the same daily dose of 
pramipexole ER tablets given once daily and pramipexole 
IR tablets given three times daily were equivalent. Moreover, 
once-daily administration of pramipexole ER tablets causes a 
smaller fluctuation in the pramipexole plasma concentration 
over 24 hours compared to the three times daily administration 
of pramipexole IR tablets. Maximum plasma concentrations 
occur at about 6 hours after administration of pramipexole ER 
tablets (Figure 1) and a steady state of exposure is reached after 
5 days of continuous dosing at the latest.13
A level A in vitro/in vivo correlation (IVIVC) was estab-
lished and evaluated for the pramipexole ER formulations.14 
Pharmacokinetic profiles for ER formulations were described 
based on the in vitro release model and the population 
pharmacokinetic model developed from the IR formulation. 
This IVIVC also showed that pramipexole of the ER formula 
was steadily absorbed all through the entire intestine including 
the colon. A pharmacokinetic-pharmacodynamic study using 
in vivo microdialysis in rats showed, in agreement with 
in vivo microdialysis measurements, a continuous decrease of 
extracellular dopamine levels and a continuous pramipexole 
exposure in rats with continuous release of pramipexole 
maintained by subcutaneous implantation of minipumps. 
In contrast, pramipexole IR (0.3 mg/kg) produced a transient 
decrease of extracellular dopamine levels over 6 hours and 
showed maximum pramipexole levels 2 hours after dosing 
which decreased over the following 6–8 hours.15
The variability among other individuals in this process was 
rather low and not influenced by other factors such as food.16
Therapeutic efficacy of pramipexole 
ER in early PD
Clinical trials of IR pramipexole have included over 
1,200 patients in the early stages of PD (disease durations up 
to 2.4 years), with 698 patients receiving pramipexole for up 
to 4 years and maintenance dose in all but one of the studies 
standardized between 0.375 and 4.5 mg of salt per day.17–21
These studies have consistently shown pramipexole 
  efficacy in treating the symptoms of early PD with 
significantly different changes versus placebo in   Unified 
Parkinson’s Disease Rating Scale (UPDRS) scores of 
2–3 points in UPDRS Part II (activities of daily living 
[ADL]), 3–5 points in UPDRS Part III (motor) scores and 
5–6.5 points in Total UPDRS scores.17,18,20 Thus, even in the 
early stages of the disease, where baseline UPDRS scores are 
lower, pramipexole provides clinically relevant efficacy.22
A randomized, double-blind, placebo and active 
  comparator-controlled trial on ER pramipexole in the early 
stage of PD was carried out by Hauser et al.23 In this study, 
259 patients were randomized (2:2:1) to double-blind 
pramipexole ER (0.375–4.5 mg, once daily), IR (0.125–
1.5 mg tid), or placebo. Patients were flexibly titrated to an 
effective dose over 7 weeks, then maintained for an additional 
26 weeks. A preplanned interim analysis at week 18 
  confirmed superiority of pramipexole ER over placebo, and in 
the final analysis at week 33, noninferiority was demonstrated 
between the two pramipexole formulations with an adjusted 
mean change in UPDRS II + III score of ‑8.6 points for ER 
(n = 213) and ‑8.8 points for IR (n = 207). The incidence 
and severity of side effects did not differ either.
Another study24 in early PD patients was carried out on 
259 early PD patients. This controlled, double-blind trial 
(ER pramipexole:IR:placebo, 2:2:1) also focused on the 
effect by employing UPDRS II and III plus Clinical Global 
Impression – Improvement (CGI-I) and Patient Global 
Impression – Improvement (PGI-I). An improvement by 
7.5 points was found in the group treated with IR pramipexole 
(n = 99). The group taking ER pramipexole (n = 99) scored 
7.4 points and the placebo group (n = 42) scored 2.7 points. 
Response rates were determined by GCI-I and PGI-I and 
were indicative of improvements for ER pramipexole at 37% 
and 35.6%, for IR pramipexole at 48% and 23.8%, and for 
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Figure 1 Simulated concentration‑time profile of pramipexole ER and pramipexole 
IR at steady state in Parkinson patients after intake of pramipexole ER 4.5  mg qd 
or pramipexole IR tid in intervals of 8 hours (8-8-8) or different intervals of 6 and 
12 hours (6-6-12).
Notes: Reproduced with permission from Eisenreich W, Sommer B, Hartter S, 
Jost WH. Pramipexole extended release: a novel treatment option in Parkinson’s 
disease. Parkinsons Dis. 2010;2010:612–619.16
Abbreviations: ER, extended release; IR, immediate release; tid, three times daily; 
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placebo at 18% and 12% in weeks 18 and 33, respectively. 
The authors concluded that both pramipexole formulas were 
safe and superior to placebo, aside from being well tolerated, 
the efficacy of ER was similar to IR with comparable adverse 
effects.
Therapeutic efficacy of pramipexole 
ER in advanced PD
Several randomized placebo-controlled trials have assessed 
the efficacy of pramipexole IR as adjunct to levodopa in 
patients suffering from levodopa motor fluctuations.25–31 
These studies consistently showed significant improvements 
of UPDRS motor and ADL scores versus placebo and Total 
UPDRS scores were improved by 20%–40% versus baseline 
(compared with 4%–13% with placebo). At the same time, 
the introduction of pramipexole adjunct therapy meant that 
patients could reduce their levodopa dose by an average 
of 30%. Retrospective analyses of randomized, placebo-
controlled trials with pramipexole, pergolide, ropinirole, 
tolcapone, or entacapone as adjuvant therapies to levodopa 
revealed that the reduction in levodopa dose was most 
significant for pramipexole and entacapone (P , 0.0001). 
In addition, the most significant reduction in OFF duration 
was with pramipexole (approximately 30% reduction) and 
entacapone (P , 0.001).32
The most significant study on ER pramipexole in the 
advanced stage of Parkinson disease was carried out by 
Schapira et al.33 In this study, patients with advanced PD 
taking levodopa plus a dopa decarboxylase inhibitor were 
randomized (1:1:1) to pramipexole ER (0.375–4.5 mg qd), 
or IR (0.125–1.5 mg tid), or placebo. Patients were flexibly 
titrated to an effective dose over 7 weeks, then maintained 
for an additional 26 weeks. The adjusted mean change in 
UPDRS II + III at Week 18 was ‑11.0 points for pramipexole 
ER, ‑12.6 points for pramipexole IR, and ‑6.3 points 
for placebo (P , 0.0002 and P , 0.0001 vs placebo, 
respectively). The adjusted mean change in   percentage OFF-
time was ‑13.3 for pramipexole ER, ‑15.7 for pramipexole 
IR, and ‑9.0 for   placebo (P = 0.0174 and P , 0.0001 vs 
placebo, respectively), corresponding to an absolute placebo-
corrected improvement of ‑0.5 hour for pramipexole ER and 
‑1.0 hour for pramipexole IR.
Dosage and administration
Pramipexole is typically initiated at a dose of 0.25 mg and 
gradually titrated to 1.5 mg tid depending on patient response. 
It should be noted that in dosing studies, the group receiving 
0.5 mg tid had benefits comparable with those receiving 
higher doses, but with fewer side effects. It is therefore 
suggested to titrate patients to 0.5 mg tid and use higher 
doses on an individual basis rather than as part of a routine 
titration schedule. Pramipexole ER tablets should be swal-
lowed whole with water, and must not be chewed, divided, 
or crushed. The tablets may be taken either with or without 
food and should be taken each day at about the same time. 
Doses of pramipexole ER should be increased gradually from 
a starting dose of 0.26 mg of base (0.375 mg of salt) per day 
and then increased as needed every 5–7 days up to a daily 
dose of 1.05 mg of base (1.5 mg of salt). If a further dose 
increase is necessary the daily dose should be increased by 
0.52 mg of base (0.75 mg of salt) at weekly intervals up to a 
maximum dose of 3.15 mg of base (4.5 mg of salt) per day. 
Studies have shown that patients already taking pramipexole 
tablets may be switched to pramipexole ER tablets overnight, 
at the same daily dose.34 After switching to pramipexole ER 
tablets, the dose may be adjusted depending on the patient’s 
therapeutic response.
A second switch study was conducted in Japan by 
Mizuno et al35 also making use of the overnight approach. 
This double-blind study was run for 12 weeks in 112 patients, 
followed by a 4-week open phase. The efficacy was assessed 
by UPDRS parts II and III. Differences in UPDRS rating 
were irrelevant (IR pramipexole 13.3, ER 13.6). The switch 
was successful in 83% of patients. The rate of adverse effects 
did not differ.
Conclusion
Current evidence favors therapy initiation in PD with a 
dopamine agonist, such as pramipexole, except for elderly 
patients or those presenting cognitive abnormalities at onset. 
However, levodopa should not be withheld from patients in 
whom adequate symptomatic control cannot be otherwise 
obtained. The choice of initial therapy will depend on the 
individuals need for symptomatic efficacy, the degree of 
motor impairment, and the risks of adverse effects.
In more advanced disease, when levodopa therapy is 
complicated by the emergence of wearing-off and other 
complications, a dopamine agonist (such as pramipexole) 
may be initiated or the current dose increased to reduce 
severity of OFF periods and to allow reduction of 
levodopa doses.
In this respect the recently introduced pramipexole 
ER formulation may present significant advantages in 
terms ensuring an improved adherence to treatment 
schedule. Compared to the IR formulation, the substance 
itself is unchanged, meaning there is an identical receptor Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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profile, identical efficacy, and identical receptor binding. 
The half-life is also the same, but the continuous release 
results in an overall prolonged plasma half-life. The 
potential advantages include maintaining more consistent 
dopaminergic activity with steadier plasma levels, increased 
tolerability, greater compliance from a simpler once-daily 
dosing regimen and ease in dose titration. In addition, 
continuous delivery of dopaminergic agents is believed 
to more closely mimic the physiological tone of the 
nigrostriatal dopamine system as opposed to pulsatile 
delivery of multiple daily doses.
ER pramipexole can be used in both early and late PD. 
A switch can take place overnight, with the ratio being 1:1. 
In most cases, the patient is not going to be affected by 
this switch. More efficaciousness, increased dyskinesia, or 
undesired effects are not to be expected. In a few cases, the 
effect may be less, which would require a dose adjustment.
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